During the Course of the Agreement Global Ventures Group Plans to Deploy SKYX’s Smart Technologies into Tens of Thousands of Homes and Hotel Rooms  SKYX Expects to Deploy Hundreds of Thousands of Products into Massive Growth of Middle East Projects SKYX’s Technologies are Expected to Offer Long-Term Recurring Revenue Opportunities… Read More..

  Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study Target Current Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body’ Treatment Investigator’s Global Assessment (IGA) Materially Improved from Baseline 4 (Severe) to 0 (Clear) Pruritus (itch) Reduced from 5… Read More..

Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) --  Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty… Read More..